During the last session, Viridian Therapeutics Inc (NASDAQ:VRDN)’s traded shares were 0.48 million, with the beta value of the company hitting 0.47. At the end of the trading day, the stock’s price was $17.04, reflecting an intraday loss of -0.53% or -$0.09. The 52-week high for the VRDN share is $27.20, that puts it down -59.62 from that peak though still a striking 41.9% gain since the share price plummeted to a 52-week low of $9.90. The company’s market capitalization is $1.39B, and the average intraday trading volume over the past 10 days was 0.76 million shares, and the average trade volume was 809.19K shares over the past three months.
Viridian Therapeutics Inc (VRDN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.27. VRDN has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 10 recommend a Buy rating for it.
Viridian Therapeutics Inc (NASDAQ:VRDN) trade information
Viridian Therapeutics Inc (VRDN) registered a -0.53% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.53% in intraday trading to $17.04, hitting a weekly high. The stock’s 5-day price performance is 8.74%, and it has moved by 10.51% in 30 days. Based on these gigs, the overall price performance for the year is -11.11%. The short interest in Viridian Therapeutics Inc (NASDAQ:VRDN) is 11.34 million shares and it means that shorts have 14.99 day(s) to cover.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 22.55% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $13.5 and $45 respectively. As a result, VRDN is trading at a discount of -164.08% off the target high and 20.77% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 31.28%. While earnings are projected to return -8.15% in 2025, the next five years will return 18.32% per annum.
VRDN Dividends
Viridian Therapeutics Inc is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Viridian Therapeutics Inc (NASDAQ:VRDN)’s Major holders
Viridian Therapeutics Inc insiders own 0.16% of total outstanding shares while institutional holders control 114.23%, with the float percentage being 114.41%. FMR LLC is the largest shareholder of the company, while 250.0 institutions own stock in it. As of 2024-06-30, the company held over 9.57 million shares (or 14.9924% of all shares), a total value of $124.55 million in shares.
The next largest institutional holding, with 4.77 million shares, is of BLACKROCK INC.’s that is approximately 7.4758% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $62.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Viridian Therapeutics Inc (VRDN) shares are Fidelity Select Portfolios-Health Care Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on May 31, 2025 indicates that Fidelity Select Portfolios-Health Care Portfolio owns about 2.63 shares. This amounts to just over 3.22 percent of the company’s overall shares, with a $44.77 million market value. The same data shows that the other fund manager holds slightly less at 2.22, or about 2.72% of the stock, which is worth about $37.82 million.
